{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T10:09:04Z","timestamp":1792922944575,"version":"4.5.0"},"reference-count":34,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T00:00:00Z","timestamp":1404777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Janssen Global Services, LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      To evaluate the effects of canagliflozin on plasma volume, urinary glucose excretion (\n                      <jats:styled-content style=\"fixed-case\">UGE<\/jats:styled-content>\n                      ), fasting plasma glucose (\n                      <jats:styled-content style=\"fixed-case\">FPG<\/jats:styled-content>\n                      ), glycated haemoglobin (\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      ) and additional measures of fluid\/electrolyte balance in patients with type 2 diabetes on background therapy with metformin and angiotensin\u2010converting enzyme inhibitors or angiotensin receptor blockers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200936) were randomized (1\u2009:\u20091) to receive canagliflozin 300\u2009mg or placebo for 12\u2009weeks. Pharmacodynamic parameters were assessed at baseline and at weeks 1 and 12.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Increased 24\u2010h\n                      <jats:styled-content style=\"fixed-case\">UGE<\/jats:styled-content>\n                      was seen in the canagliflozin group compared with a reduction in the placebo group at both week 1 (91.8 vs. \u22122.4\u2009g) and week 12 (82.6 vs. \u22120.4\u2009g). Canagliflozin also reduced both\n                      <jats:styled-content style=\"fixed-case\">FPG<\/jats:styled-content>\n                      and\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      . Reductions in body weight and blood pressure were observed at weeks 1 and 12. Canagliflozin decreased plasma volume compared with an increase with placebo at week 1 (\u22125.4 vs. 4.3%; p\u2009=\u20090.02), but this was largely attenuated at week 12 (4.6 vs. 5.8%; p\u2009=\u20090.76). A modest numerical increase in urine volume was observed with canagliflozin at week 1 that was attenuated at week 12; other measures of volume status (i.e. blood urea nitrogen, serum creatinine and haematocrit) remained modestly increased with canagliflozin at week 12.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Canagliflozin provided sustained effects on\n                      <jats:styled-content style=\"fixed-case\">UGE<\/jats:styled-content>\n                      and\n                      <jats:styled-content style=\"fixed-case\">FPG<\/jats:styled-content>\n                      over 12\u2009weeks and a transient reduction in plasma volume that was largely attenuated by week 12.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.12322","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T09:43:57Z","timestamp":1402998237000},"page":"1087-1095","source":"Crossref","is-referenced-by-count":219,"title":["Effect of the sodium glucose co\u2010transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus"],"prefix":"10.1111","volume":"16","author":[{"given":"S.","family":"Sha","sequence":"first","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Polidori","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Heise","sequence":"additional","affiliation":[{"name":"Profil  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Natarajan","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Farrell","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.\u2010S.","family":"Wang","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sica","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University Medical Center  Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rothenberg","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Plum\u2010M\u00f6rschel","sequence":"additional","affiliation":[{"name":"Profil  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,7,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12090"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3810\/hp.2013.04.1020"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60683-2"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12322"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.850066"},{"issue":"1","key":"e_1_2_7_10_1","first-page":"LB18","article-title":"Canagliflozin (CANA) demonstrates durable glycemic improvements over 104 weeks versus glimepiride (GLIM) in subjects with type 2 diabetes mellitus (T2DM) on metformin (MET) (Abstract 65\u2010LB)","volume":"62","author":"Cefalu WT","year":"2013","journal-title":"Diabetes"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.87"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802710422"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4205"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.88"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1926"},{"key":"e_1_2_7_16_1","unstructured":"INVOKANA\u2122 (canagliflozin) tablets for oral use [package insert]. Titusville NJ: Janssen Pharmaceuticals 2013."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12127"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1213829"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2007.13.s8-b.9"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(93)90183-4"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00740.2006"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001340100942"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1088\/0967-3334\/29\/7\/005"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/clinchem\/35.10.2124","article-title":"Antipyrine, indocyanine green, and lorazepam determined in plasma by high\u2010pressure liquid chromatography","volume":"35","author":"Awni WM","year":"1989","journal-title":"Clin Chem"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4682-11-33"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.24.5.1197"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1980.tb09718.x"},{"key":"e_1_2_7_30_1","volume-title":"Textbook of Medical Physiology","author":"Guyton AC","year":"2010"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60812-X"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(78)90303-4"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)90734-4"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050197"},{"issue":"1","key":"e_1_2_7_35_1","first-page":"A278","article-title":"Lower blood pressure (BP) with canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) (Abstract 1077\u2010P)","volume":"62","author":"Weir MR","year":"2013","journal-title":"Diabetes"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12322","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:57:25Z","timestamp":1761886645000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,8]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1111\/dom.12322"],"URL":"https:\/\/doi.org\/10.1111\/dom.12322","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,8]]}}}